Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 8
Submit an article Journal homepage
389
Views
28
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma

Christiane QuerfeldCorrespondence[email protected]
,
Timothy M. Kuzel
,
Youn H. KimStanford Cancer Center, Stanford, CA, USA
,
Pierluigi PorcuDepartment of Internal Medicine, Division of Hematology/Oncology, Ohio State University, Columbus, OH, USA
,
Madeleine DuvicDepartment of Dermatology, University of Texas and M. D. Anderson Cancer Center, Houston, TX, USA
,
Amy MusiekDepartment of Dermatology, University of Pennsylvania Health System, Philadelphia, PA, USA
,
Alain H. RookDepartment of Dermatology, University of Pennsylvania Health System, Philadelphia, PA, USA
,
Lawrence A. MarkDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA
,
Lauren Pinter-brownDepartment of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
,
Oday HamidEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA
,
Boris LinEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA
,
Ying BianEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA
,
Mark BoyeEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA
,
Jeannette M. Dayi3 Statprobe, Cary, NC, USA
&
Steven T. Rosen
 show all
Pages 1474-1480 | Received 30 Dec 2010, Accepted 10 Mar 2011, Published online: 08 Jun 2011

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ignace Vergote. (2014) Novel therapies, including enzastaurin, in the treatment of ovarian cancer. Expert Opinion on Investigational Drugs 23:5, pages 579-598.
Read now
Deborah A Katz, Janet MD Plate, Sunita Nathan & Lydia Usha. (2012) Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review. Orphan Drugs: Research and Reviews 2, pages 1-12.
Read now

Articles from other publishers (26)

Angelo Aquino, Nicoletta Bianchi, Anna Terrazzan & Ornella Franzese. (2023) Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response. Biology 12:8, pages 1047.
Crossref
He-qiang Zhang, Jia-le Lin, Lei Pan, Liang Mao, Jing-long Pang, Qian Yuan, Gui-yang Li, Gang-si Yi, Yang-bin Lin, Bao-long Feng, Yun-da Li, Yan Wang, Ling-jun Jie & Yan-hui Zhang. (2023) Enzastaurin cardiotoxicity: QT interval prolongation, negative inotropic responses and negative chronotropic action. Biochemical Pharmacology 209, pages 115443.
Crossref
Natalia Rendón‐Serna, Luis A. Correa‐Londoño, Margarita M. Velásquez‐Lopera & Maria Bermudez‐Muñoz. (2021) Cell signaling in cutaneous T‐cell lymphoma microenvironment: promising targets for molecular‐specific treatment. International Journal of Dermatology 60:12, pages 1462-1480.
Crossref
Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata & Jeong-Hun Kang. (2021) Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials. Pharmaceutics 13:11, pages 1748.
Crossref
I. P. Kolpaksidi, M. V. Dmitrieva, I. V. Yarosh & I. I. Krasnyuk. (2021) ANTITUMOR DRUGS BASED ON INDOLOCARBAZOL DERIVATIVES. Pharmacy & Pharmacology 9:4, pages 252-265.
Crossref
Xu Hannah Zhang, Sangkil Nam, Jun Wu, Chih-Hong Chen, Xuxiang Liu, Hongzhi Li, Timothy McKeithan, Qiang Gong, Wing C. Chan, Hongwei Holly Yin, Yate-Ching Yuan, Raju Pillai, Christiane Querfeld, David Horne, Yuan Chen & Steven T. Rosen. (2018) Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology 138:11, pages 2377-2387.
Crossref
Vincent Prêtre & Andreas Wicki. (2018) Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?. Seminars in Cancer Biology 48, pages 70-77.
Crossref
Lisa Argnani, Alessandro Broccoli & Pier Luigi Zinzani. (2017) Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treatment Reviews 61, pages 61-69.
Crossref
T. Bourhill, A. Narendran & R.N. Johnston. (2017) Enzastaurin: A lesson in drug development. Critical Reviews in Oncology/Hematology 112, pages 72-79.
Crossref
Sean J. Whittaker & Fiona Child. 2016. Rook's Textbook of Dermatology, Ninth Edition. Rook's Textbook of Dermatology, Ninth Edition 1 66 .
Julia J. Scarisbrick. (2016) New drugs in cutaneous T-cell lymphomas. Current Opinion in Oncology 28:5, pages 384-389.
Crossref
Xueying Li, Xiaojie Fang, Su Li, Weijing Zhang, Nong Yang, Yimin Cui, He Huang, Ruiqing Cai, Xiaoting Lin, Xiaohong Fu, Huangming Hong & Tongyu Lin. (2016) A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma. Oncotarget 7:14, pages 18585-18593.
Crossref
Ryan A. Wilcox. (2015) A three‐signal model of T ‐cell lymphoma pathogenesis . American Journal of Hematology 91:1, pages 113-122.
Crossref
Annarita Miluzio, Stefania Oliveto, Elisa Pesce, Luciano Mutti, Bruno Murer, Stefano Grosso, Sara Ricciardi, Daniela Brina & Stefano Biffo. (2015) Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo . Oncotarget 6:35, pages 37471-37485.
Crossref
Meghan Bliss-Moreau, Cristian Coarfa, Preethi H. Gunaratne, Joan Guitart, Nancy L. Krett & Steven T. Rosen. (2015) Identification of p38β as a Therapeutic Target for the Treatment of Sézary Syndrome. Journal of Investigative Dermatology 135:2, pages 599-608.
Crossref
R Garg, L G Benedetti, M B Abera, H Wang, M Abba & M G Kazanietz. (2013) Protein kinase C and cancer: what we know and what we do not. Oncogene 33:45, pages 5225-5237.
Crossref
Lisa Lange, Sarah Keppner-Witter, Juline Grigat & Birgit Spänkuch. (2014) Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget 5:8, pages 2263-2275.
Crossref
T. Beynon, E. Radcliffe, F. Child, D. Orlowska, S. Whittaker, S. Lawson, L. Selman & R. Harding. (2014) What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence. British Journal of Dermatology 170:3, pages 599-608.
Crossref
Sarah I. Jawed, Patricia L. Myskowski, Steven Horwitz, Alison Moskowitz & Christiane Querfeld. (2014) Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Journal of the American Academy of Dermatology 70:2, pages 223.e1-223.e17.
Crossref
Mehdi Hamadani, Sarah M. Abu Kar, Saad Z. Usmani, Bipin N. Savani, Ernesto Ayala & Mohamed A. Kharfan-Dabaja. (2014) Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas. Seminars in Hematology 51:1, pages 73-86.
Crossref
Jasmine Zain, Michael Weichenthal, Scott Rodig & Jan Delabie. 2014. Rare Lymphomas. Rare Lymphomas 133 167 .
Stéfano M. Cirigliano, Laura V. Mauro, Valeria C. Grossoni, Lucas L. Colombo, Miriam J. Diament, Marcelo G. Kazanietz, Elisa D. Bal de Kier Joffé, Lydia I. Puricelli & Alejandro J. Urtreger. (2013) Modulation of Pancreatic Tumor Potential by Overexpression of Protein Kinase C β1. Pancreas 42:7, pages 1060-1069.
Crossref
Ignace B. VergoteRadoslav ChekerovFrederic AmantPhilipp HarterAntonio CasadoJanusz EmerichThomas BauknechtKambiz MansouriScott P. MyrandTuan S. NguyenPeipei ShiJalid Sehouli. (2013) Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer. Journal of Clinical Oncology 31:25, pages 3127-3132.
Crossref
Franck Morschhauser, Olivier Fitoussi, Corinne Haioun, Catherine Thieblemont, Hang Quach, Richard Delarue, Sylvie Glaisner, Jean Gabarre, André Bosly, John Lister, Ju Li & Bertrand Coiffier. (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. European Journal of Cancer 49:13, pages 2869-2876.
Crossref
Salvia Jain, Jasmine Zain & Owen O’Connor. (2012) Novel therapeutic agents for cutaneous T-Cell lymphoma. Journal of Hematology & Oncology 5:1.
Crossref
Uwe Wollina. (2012) Cutaneous T cell lymphoma: update on treatment. International Journal of Dermatology 51:9, pages 1019-1036.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.